Halozyme Therapeutics, Inc.
Country not established
- Devices
- 1
What Halozyme Therapeutics, Inc. makes
Halozyme Therapeutics, Inc. manufactures CUMULASE, an enzyme-based pharmaceutical excipient designed to enhance the absorption of injectable drug formulations by modifying subcutaneous tissue.
CUMULASE is classified as a Class II medical device under FDA regulations and is listed in the FDA’s 510(k) clearance registry. The company is headquartered in the United States.
Catalogue
Cumulase Ref K042495
Regimes: 510(k) Registry: 510(k)
Frequently asked questions
How many devices does Halozyme Therapeutics, Inc. have in the registry?
The registry currently lists 1 device for Halozyme Therapeutics, Inc.. Devices recorded under merged duplicate company entries are counted once.
Which registries list Halozyme Therapeutics, Inc.'s devices?
Among its 1 most recently registered device, Halozyme Therapeutics, Inc. has devices listed in FDA 510(k) (1 device).
What risk classes do Halozyme Therapeutics, Inc.'s devices fall under?
Among its 1 most recently registered device, the classes recorded for Halozyme Therapeutics, Inc.'s devices are Class II. Each device page shows its own class and authorisation.
What are the newest devices from Halozyme Therapeutics, Inc. in the registry?
The most recently registered devices listed for Halozyme Therapeutics, Inc. include CUMULASE.